(Q38137016)

29 August 2017

title

A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery (English)

1 reference

29 August 2017

1 reference

1 reference

Neil R Smith

1

1 reference

29 August 2017

Christopher Womack

series ordinal

2

1 reference

29 August 2017

publication date

1 January 2014

1 reference

29 August 2017

1 reference

29 August 2017

volume

232

1 reference

29 August 2017

issue

2

1 reference

29 August 2017

page(s)

190-198

1 reference

Pharmacodynamic biomarkers for molecular cancer therapeutics

29 August 2017

cites work

1 reference

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development

21 January 2018

1 reference

Biomarkers in oncology drug development

21 January 2018

1 reference

Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine

21 January 2018

1 reference

Companion biomarkers: paving the pathway to personalized treatment for cancer

21 January 2018

1 reference

Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS

21 January 2018

1 reference

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

21 January 2018

1 reference

The use of immunohistochemistry for biomarker assessment--can it compete with other technologies?

21 January 2018

1 reference

Biomarker method validation in anticancer drug development

21 January 2018

1 reference

Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology

21 January 2018

1 reference

Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.4262

1 reference

29 August 2017

1 reference